Last reviewed · How we verify

NCT04416997

Rheumatoid Arthritis Hematological Indices

Status unknown Last updated 4 June 2020
What this trial tests

trial testing Blood and serum samples in Rheumatoid Arthritis in 40 participants. Status unknown.

Timeline
1 March 2020
Primary endpoint
29 October 2022
30 January 2023

Quick facts

Lead sponsorAssiut University
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment40
Start date1 March 2020
Primary completion29 October 2022
Estimated completion30 January 2023
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Assiut University

Who can join

Eligibility, any sex, with Rheumatoid Arthritis or Serum Albumin Low. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Rheumatoid arthritis is a chronic systemic inflammatory and autoimmune disease, characterized by disordered immunity, not regulated cytokines and inflammatory infiltration of the synovial joints. It is the most common inflammatory erosive poly arthritis affecting around 0.5-1% of the worldwide population which leads to joint damage and disability

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Rheumatoid Arthritis

Currently open trials in the same condition.

Other Assiut University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04416997.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing